WO2003059899A1 - Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof - Google Patents
Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof Download PDFInfo
- Publication number
- WO2003059899A1 WO2003059899A1 PCT/US2003/000300 US0300300W WO03059899A1 WO 2003059899 A1 WO2003059899 A1 WO 2003059899A1 US 0300300 W US0300300 W US 0300300W WO 03059899 A1 WO03059899 A1 WO 03059899A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxy
- amide
- oxo
- fluoro
- dihydroisobenzofuran
- Prior art date
Links
- 0 *C(*)(*)CC(CBr)=O Chemical compound *C(*)(*)CC(CBr)=O 0.000 description 2
- KGFMFEQQZNKWLP-UHFFFAOYSA-N CC(C)(CC(Cc1ccccc1)(C(Nc(cc1)cc(CO2)c1C2=O)=O)O)c(cc(cc1)F)c1O Chemical compound CC(C)(CC(Cc1ccccc1)(C(Nc(cc1)cc(CO2)c1C2=O)=O)O)c(cc(cc1)F)c1O KGFMFEQQZNKWLP-UHFFFAOYSA-N 0.000 description 1
- GGQRUDKBZGUEAN-UHFFFAOYSA-N CC(C)(CC(Cc1ccccc1)(C(Nc(cc1CO2)ccc1C2=O)=O)O)c(cc(cc1)F)c1OC Chemical compound CC(C)(CC(Cc1ccccc1)(C(Nc(cc1CO2)ccc1C2=O)=O)O)c(cc(cc1)F)c1OC GGQRUDKBZGUEAN-UHFFFAOYSA-N 0.000 description 1
- BXAHGSPNVLQIJJ-UHFFFAOYSA-N Cc(cc1)cc(CO2)c1C2=O Chemical compound Cc(cc1)cc(CO2)c1C2=O BXAHGSPNVLQIJJ-UHFFFAOYSA-N 0.000 description 1
- CSWMCUWOGVIIBP-UHFFFAOYSA-N Cc(cc1C(C)=NO2)ccc1C2=O Chemical compound Cc(cc1C(C)=NO2)ccc1C2=O CSWMCUWOGVIIBP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
Definitions
- the p resent i nvention r elates to g lucocorticoid m imetics or ligands, m ethods of m aking such compounds, their use in pharmaceutical compositions, and their use in modulating the glucocorticoid receptor function, treating disease-states or conditions mediated by the glucocorticoid receptor function in a patient in need of such treatment, and other uses.
- COPD chronic obstructive pulmonary disease
- other immune and inflammatory diseases including Crohn disease, ulcerative colitis, systemic lupus erythematosus, autoimmune chronic active hepatitis, osteoarthritis, tendonitis, and bursitis (J. Toogood, Glucocorticoids, NJ. Goulding and RJ. Flowers (eds.), Boston: Birkhauser, 2001, pp. 161-174). They have also been used to help prevent rejection in organ transplantation.
- ligands for the glucocorticoid receptor that are highly selective and, upon binding, can dissociate the transactivation and transrepression pathways, providing therapeutic agents with a reduced side effect profile.
- Assay systems to determine effects on transactivation and transrepression have been described (e.g., CM. Bamberger and H.M. Schulte, Eur. J. Clin. Invest., 2000, 30 (suppl. 3), pp. 6-9).
- Selectivity for the glucocorticoid receptor may be determined by comparing the binding affinity for this receptor with that of other steroid family receptors including those mentioned above.
- a compound that is found to interact with the glucocorticoid receptor in a binding assay could be an agonist or an antagonist.
- the agonist properties of the compound could be evaluated in the transactivation or transrepression assays described above.
- the compound may be found to have antagonist activity.
- glucocorticoids stimulate glucose production in the liver.
- R 2 and R 3 are each independently C 1 -C 3 alkyl, or R 2 and R 3 together with the carbon atom they are commonly attached to form a C 3 -C 6 spiro cycloalkyl ring;
- the compounds according to the invention are formulated into pharmaceutical compositions comprising an effective amount, preferably a pharmaceutically effective amount, of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof, and a pharmaceutically acceptable excipient or carrier.
- the invention also provides a method of modulating the glucocorticoid receptor function in a patient, the method comprising administering to the patient an effective amount of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.
- the invention further provides a method of treating a disease-state or condition mediated by the glucocorticoid receptor function in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.
- the invention also provides a method of treating a disease-state or condition selected from: type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma, in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.
- a disease-state or condition selected from: type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma
- the invention provides a method of treating a disease characterized by inflammatory, allergic, or proliferative processes, in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.
- the disease characterized by inflammatory, allergic, or proliferative processes is selected from: (i) lung diseases; (ii) rheumatic diseases or autoimmune diseases or j oint diseases; (iii) allergic diseases; (iv) vasculitis diseases; (v) dermatological diseases; (vi) renal diseases; (vii) hepatic diseases; (viii) gastrointestinal diseases; (ix) proctological diseases; (x) eye diseases; (xi) diseases of the ear, nose, and throat (ENT) area; (xii) neurological diseases; (xiii) blood diseases; (xiv) tumor diseases; (xv) endocrine diseases; (xvi) organ and tissue transplantations and graft- versus-host diseases; (xvii) severe states of shock; (xviii) substitution therapy; and (xix) pain of inflammatory genesis.
- the disease characterized by inflammatory, allergic, or proliferative processes is selected from: type I diabetes, osteoarthritis, Guillain-Barre syndrome, restenosis following percutaneous transluminal coronary angioplasty, Alzheimer disease, acute and chronic pain, atherosclerosis, reperfusion injury, bone reso ⁇ tion diseases, congestive heart failure, myocardial infarction, thermal injury, multiple organ injury secondary to trauma, acute purulent meningitis, necrotizing enterocolitis, and syndromes associated with hemodialysis, leukopheresis, and granulocyte transfusion.
- type I diabetes type I diabetes, osteoarthritis, Guillain-Barre syndrome, restenosis following percutaneous transluminal coronary angioplasty, Alzheimer disease, acute and chronic pain, atherosclerosis, reperfusion injury, bone reso ⁇ tion diseases, congestive heart failure, myocardial infarction, thermal injury, multiple organ injury secondary to trauma, acute purulent meningitis, necrotizing enterocolitis, and
- the invention further provides a method of assaying the glucocorticoid receptor function in a sample, comprising: (a) contacting the sample with a selected amount of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof; and (b) detecting the amount of the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof bound to glucocorticoid receptors in the sample.
- the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof is labeled with a detectable marker selected from: a radiolabel, fluorescent tag, a chemiluminescent tag, a chromophore, and a spin label.
- a detectable marker selected from: a radiolabel, fluorescent tag, a chemiluminescent tag, a chromophore, and a spin label.
- the invention also provides a method of imaging the glucocorticoid receptor distribution in a sample or patient, the method comprising: (a) contacting the sample or administering to a patient a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof having a detectable marker; (b) detecting the spatial distribution and amount of the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof having a detectable marker bound to glucocorticoid receptors in the sample or patient using an imaging means to obtain an image; and (c) displaying an image of the spatial distribution and amount of the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof having a detectable marker bound to glucocorticoid receptors in the sample.
- the imaging means is selected from: radioscintigraphy, nuclear magnetic resonance imaging (MRI), computed tomography (CT scan), or positron emission to
- the invention also provides a kit for the in vitro diagnostic determination of the glucocorticoid receptor function in a sample, comprising: (a) a diagnostically effective amount of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof; and (b) instructions for use of the diagnostic kit.
- the invention also provides a method of making a compound of Formula (I)
- V I (R 4 is C O) j or
- the invention further provides a method of making a compound of Formula (I)
- R 1 , R 2 , R 3 , R 5 , and R 6 are as defined above and R 4 is CH 2 , the method comprising: (a) reacting an aryl or heteroaryl bromide with a suitable organometallic reagent in a suitable solvent and treating the resulting anion with a solution of cuprous iodide in dimethylsulfide followed by a methyl vinyl ketone of Formula (VII) bearing R 2 and R 3 to form a methyl ketone of Formula (VIII)
- VIM IX (c) reacting the bromoketone of Formula (IX) with an amine R 6 NH 2 in a suitable solvent to form an aminoketone of Formula (X)
- d-Cio alkyl means an alkyl group or radical having 1 to 10 carbon atoms.
- lower applied to any carbon-containing group means a group containing from 1 to 8 carbon atoms, as appropriate to the group (i.e., a cyclic group must have at least 3 atoms to constitute a ring).
- alkylaryl means a monovalent radical of the formula Alk-Ar-
- arylalkyl m eans a monovalent radical of the formula Ar-Alk- (where Alk is an alkyl group and Ar is an aryl group).
- a term designating a monovalent radical where a divalent radical is appropriate shall be construed to designate the respective divalent radical and vice versa.
- conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups.
- alkyl or "alkyl group” mean a branched or straight-chain saturated aliphatic hydrocarbon monovalent radical. This term is exemplified by groups such as methyl, ethyl, ?z-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (tert-butyl), and the like. It may be abbreviated "Alk”.
- alkenyl or "alkenyl group” mean a branched or straight-chain aliphatic hydrocarbon monovalent radical containing at least one carbon-carbon double bond. This term is exemplified by groups such as ethenyl, propenyl, w-butenyl, isobutenyl, 3- methylbut-2-enyl, 7?-pentenyl, heptenyl, octenyl, decenyl, and the like.
- alkynyl or "alkynyl group” mean a branched or straight-chain aliphatic hydrocarbon monovalent radical containing at least one carbon-carbon triple bond. This term is exemplified by groups such as ethynyl, propynyl, n-butynyl, 2-butynyl, 3- methylbutynyl, n-pentynyl, heptynyl, octynyl, decynyl, and the like.
- alkylene or "alkylene group” mean a branched or straight-chain saturated aliphatic hydrocarbon divalent radical having the specified number of carbon atoms. This term is exemplified by groups such as methylene, ethylene, propylene, ra-butylene, and the like, and may alternatively and equivalently be denoted herein as -(alkyl)-.
- alkenylene or "alkenylene group” mean a branched or straight-chain aliphatic hydrocarbon divalent radical having the specified number of carbon atoms and at least one carbon-carbon double bond. This term is exemplified by groups such as ethenylene, propenylene, ⁇ z-butenylene, and the like, and may alternatively and equivalently be denoted herein as -(alkylenyl)-.
- alkynylene or "alkynylene group” mean a branched or straight-chain aliphatic hydrocarbon divalent radical containing at least one carbon-carbon triple bond. This term is exemplified by groups such as ethynylene, propynylene, n-butynylene, 2-butynylene, 3- methylbutynylene, ra-pentynylene, heptynylene, octynylene, decynylene, and the like, and may alternatively and equivalently be denoted herein as -(alkynyl)-.
- alkoxy or "alkoxy group” mean a monovalent radical of the formula AlkO, where Alk is an alkyl group. This term is exemplified by groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, .yec-butoxy, tert-butoxy, pentoxy, and the like.
- aryloxy means a monovalent radical of the formula ArO-, where Ar is aryl. This term is exemplified by groups such as phenoxy, naphthoxy, and the like.
- alkylcarbonyl means a monovalent radical of the formula AlkC(O)-, where Alk is alkyl or hydrogen.
- arylcarbonyl means a monovalent radical of the formula ArC(O)-, where Ar is aryl.
- acyl or "acyl group” mean a monovalent radical of the formula RC(O)-, where R is a substituent selected from hydrogen or an organic substituent.
- substituents include alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, and the like. As such, the terms comprise alkylcarbonyl groups and arylcarbonyl groups.
- acylamino or "acylamino group” mean a monovalent radical of the formula RC(0)N(R)-, where each R is a substituent selected from hydrogen or a substituent group.
- alkoxycarbonyl or “alkoxycarbonyl group” mean a monovalent radical of the formula AlkO-C(O)-, where Alk is alkyl.
- exemplary alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, tert-butyloxycarbonyl, and the like.
- alkylcarbonyloxy or “alkylcarbonyloxy group” or “alkanoyloxy” or “alkanoyloxy group” mean a monovalent radical of the formula AlkC(O)0-, where Alk is alkyl.
- arylcarbonyloxy or "arylcarbonyloxy group” or “aroyloxy” or “aroyloxy group” mean a monovalent radical of the formula ArC(O)O-, where Ar is aryl.
- alkylaminocarbonyloxy or “alkylaminocarbonyloxy group” mean a monovalent radical of the formula R 2 NC(0)0-, where each R is independently hydrogen or lower alkyl.
- alkoxycarbonylammo or "alkoxycarbonylammo group” mean a monovalent radical of the formula ROC(0)NH-, where R is lower alkyl.
- alkylcarbonylamino or “alkylcarbonylamino group” or “alkanoylamino” or “alkanoylamino groups” mean a monovalent radical of the formula AlkC(0)NH-, where Alk is alkyl.
- alkylcarbonylamino groups include acetamido (CH 3 C(0)NH-).
- alkylaminocarbonyloxy or “alkylaminocarbonyloxy group” mean a monovalent radical of the formula AlkNHC(0)0-, where Alk is alkyl.
- amino or “amino group” mean an -NH 2 group.
- alkylamino or “alkylamino group” mean a monovalent radical of the formula (Alk)NH-, where Alk is alkyl.
- alkylamino groups include methylamino, ethylamino, propylamino, butylamino, tert-butylamino, and the like.
- dialkylamino or "dialkylamino group” mean a monovalent radical of the formula (Alk)(Alk)N-, where each Alk is independently alkyl.
- Exemplary dialkylamino groups include dimethylamino, methylethylamino, diethylamino, dipropylamino, ethylpropylamino, and the like.
- substituted amino or “substituted amino group” mean a monovalent radical of the formula -NR 2 , where each R is independently a substituent selected from hydrogen or the specified substituents (but where both Rs cannot be hydrogen).
- substituents include alkyl, alkanoyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, and the like.
- alkoxycarbonylammo or "alkoxycarbonylammo group” mean a monovalent radical of the formula AlkOC(0)NH-, where Alk is alkyl.
- ureido or "ureido group” mean a monovalent radical of the formula R 2 NC(0)NH-, where each R is independently hydrogen or alkyl.
- halo means one or more hydrogen atoms of the group are replaced by halogen groups.
- haloalkyl or "haloalkyl group” mean a branched or straight-chain saturated aliphatic hydrocarbon monovalent radical, wherein one or more hydrogen atoms thereof are each independently replaced with halogen atoms. This term is exemplified by groups such as chloromethyl, 1,2-dibromoethyl, 1,1,1-trifluoropropyl, 2-iodobutyl, l-chloro-2- bromo-3-fluoropentyl, and the like.
- alkylthio or "alkylthio group” mean a monovalent radical of the formula AlkS-, where Alk is alkyl.
- exemplary groups include methylthio, ethylthio, n-propylthio, isopropylthio, »-butylthio, and the like.
- sulfonyl or “sulfonyl group” mean a divalent radical of the formula -S0 2 -.
- sulfonylamino or “sulfonylamino group” mean a divalent radical of the formula -SO 2 NR-, where R is a hydrogen or a substituent group.
- aminonosulfonyl or “aminosulfonyl group” mean a monovalent radical of the formula NR 2 S0 2 -, where R is each independently a hydrogen or a substituent group.
- carbocycle or “carbocyclic group” mean a stable aliphatic 3- to 15-membered monocyclic or polycyclic monovalent or divalent radical consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the carbocycle may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
- the term comprises cycloalkyl (including spiro cycloalkyl), cycloalkylene, cycloalkenyl, cycloalkenylene, cycloalkynyl, and cycloalkynylene, and the like.
- cycloalkyl or "cycloalkyl group” mean a stable aliphatic saturated 3- to 15- membered monocyclic or polycyclic monovalent radical consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the cycloalkyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
- Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornanyl, adamantyl, tetrahydronaphthyl (tetralin), 1-decalinyl, bicyclo[2.2.2]octanyl, 1- methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and the like.
- cycloalkenyl or “cycloalkenyl group” mean a stable aliphatic 5- to 15- membered monocyclic or polycyclic monovalent radical having at least one carbon-carbon double bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10- membered bicyclic ring.
- the cycloalkenyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
- Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, norbornenyl, 2-methylcyclopentenyl, 2-methylcyclooctenyl, and the like.
- cycloalkynyl or “cycloalkynyl group” mean a stable aliphatic 8- to 15- membered monocyclic or polycyclic monovalent radical having at least one carbon-carbon triple bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 8- to 10-membered monocyclic or 12- to 15- membered bicyclic ring.
- the cycloalkynyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
- Exemplary cycloalkynyl groups include, cyclooctynyl, cyclononynyl, cyclodecynyl, 2- methylcyclooctynyl, and the like.
- cycloalkylene or "cycloalkylene group” mean a stable saturated aliphatic 3- to 15-membered monocyclic or polycyclic divalent radical consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the cycloalkyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
- Exemplary cycloalkylene groups include cyclopentylene, and the like.
- cycloalkenylene or "cycloalkenylene group” mean a stable aliphatic 5- to 15- membered monocyclic or polycyclic divalent radical having at least one carbon-carbon double bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10- membered bicyclic ring.
- the cycloalkenylene ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
- Exemplary cycloalkenylene groups include cyclopentenylene, cyclohexenylene, cycloheptenylene, cyclooctenylene, cyclononenylene, cyclodecenylene, norbornenylene, 2- methylcyclopentenylene, 2-methylcyclooctenylene, and the like.
- cycloalkynylene or "cycloalkynylene group” mean a stable aliphatic 8- to 15- membered monocyclic or polycyclic divalent radical having at least one carbon-carbon triple bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 8- to 10-membered monocyclic or 12- to 15- membered bicyclic ring. Unless otherwise specified, the cycloalkynylene ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
- Exemplary cycloalkynylene groups include cyclooctynylene, cyclononynylene, cyclodecynylene, 2- methylcyclooctynylene, and the like.
- aryl or “aryl group” mean an aromatic carbocyclic monovalent or divalent radical of from 6 to 14 carbon atoms having a single ring (e.g., phenyl or phenylene) or multiple condensed rings (e.g., naphthyl or anthranyl). Unless otherwise specified, the aryl ring may be attached at any suitable carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
- Exemplary aryl groups include phenyl, naphthyl, anthryl, phenanthryl, indanyl, indenyl, biphenyl, and the like. It may be abbreviated "Ar".
- heteroaryl or “heteroaryl group” mean a stable aromatic 5- to 14-membered, monocyclic or polycyclic monovalent or divalent radical which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic radical, having from one to four heteroatoms in the ring(s) independently selected from nitrogen, oxygen, and sulfur, wherein any sulfur heteroatoms may optionally be oxidized and any nitrogen heteroatom may optionally be oxidized or be quatemized.
- the heteroaryl ring may be attached at any suitable heteroatom or carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable heteroatom or carbon atom which results in a stable structure.
- exemplary and preferred heteroaryls include furanyl, thienyl, pynolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, azaindolizinyl, indolyl, azaindolyl, diazaindolyl, dihydroindolyl, dihydroazaindoyl, isoindolyl, aza
- heterocycle means a stable non-aromatic 5- to 14-membered monocyclic or polycyclic, monovalent or divalent, ring which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 1 0-membered bicyclic ring, having from one to three heteroatoms in the ring(s) independently selected from nitrogen, oxygen, and sulfur, wherein any sulfur heteroatoms may optionally be oxidized and any nitrogen heteroatom may optionally be oxidized or be quatemized.
- the heterocyclyl ring may be attached at any suitable heteroatom or carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable heteroatom or carbon atom which results in a stable structure.
- exemplary and prefened heterocycles include pyrrolinyl, pynolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, mo ⁇ holinyl, thiomo ⁇ holinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, hexahydropyrimidinyl, hexahydropyridazinyl, and the like.
- stable compound or “stable structure” mean a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic or diagnostic agent.
- a compound which would have a "dangling valency" or is a carbanion is not a compound contemplated by the invention.
- substituted means that any one or more hydrogens on an atom of a group or moiety, whether specifically designated or not, is replaced with a selection from the indicated group of substituents, provided that the atom's normal valency is not exceeded and that the substitution results in a stable compound. If a bond to a substituent is shown to cross the bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound, then such substituent may be bonded via any atom in such substituent.
- such piperazinyl, piperidinyl, or tetrazolyl group may be bonded to the rest of the compound of the invention via any atom in such piperazinyl, piperidinyl, or tetrazolyl group.
- any substituent or group occurs more than one time in any constituent or compound, its definition on each occurrence is independent of its definition at every other occunence.
- the term “about” or “approximately” means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.
- prodrugs themselves have weak or no biological activity and are stable under ordinary conditions.
- Prodrugs can be readily prepared from the parent compounds using methods known in the art, such as those described in A T extbook o f Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, particularly Chapter 5: "Design and Applications of Prodrugs”; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, K.B. Sloan (ed.), Marcel Dekker, 1 998; M ethods i n E nzvmology. K .
- salt means an ionic form of the parent compound or the product of the reaction between the parent compound with a suitable acid or base to make the acid salt or base salt of the parent compound.
- Salts of the compounds of the present invention can be synthesized from the parent compounds which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid parent compound with stoichiometric amounts or with an excess of the desired salt- forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
- pharmaceutically acceptable salt means a salt of a compound of the invention which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, generally water or oil- soluble or dispersible, and effective for their intended use.
- pharmaceutically-acceptable acid addition salts and pharmaceutically-acceptable base addition salts.
- the compounds of the present invention are useful in both free base and salt form, in practice, the use of the salt form amounts to use of the base form. Lists of suitable salts are found in, e.g., S.M. Birge et al, J. Pharm. Sci., 1977, 66, pp. 1-19, which is hereby inco ⁇ orated by reference in its entirety.
- pharmaceutically-acceptable base addition salt means those salts which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable, formed with inorganic bases such as ammonia or hydroxide, carbonate, or bicarbonate of ammonium or a metal cation such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Particularly prefened are the ammonium, potassium, sodium, calcium, and magnesium salts.
- Salts derived from pharmaceutically-acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, quaternary amine compounds, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion- exchange resins, such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N- ⁇ ethylpiperidine, tetramethylammonium compounds, tetraethylam
- solvate means a physical association of a compound with one or more solvent molecules or a complex of variable stoichiometry formed by a solute (for example, a compound of Formula (I)) and a solvent, for example, water, ethanol, or acetic acid. This physical association may involve varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are inco ⁇ orated in the crystal lattice of the crystalline solid. In general, the solvents selected do not interfere with the biological activity of the solute. Solvates encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like.
- hydrate means a solvate wherein the solvent molecule(s) is/are H 2 0.
- stereoisomer means a stable isomer that has at least one chiral atom or restricted rotation giving rise to pe ⁇ endicular dissymmetric planes (e.g., certain biphenyls, allenes, and spiro compounds) and can rotate plane-polarized light. Because asymmetric centers and other chemical structure exist in the compounds of the invention which may give rise to optical isomerism, the invention contemplates stereoisomers and mixtures thereof.
- the compounds of the invention and their salts include asymmetric carbon atoms and may therefore exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as a racemic mixture.
- Such compounds can be prepared or isolated as pure optical isomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures.
- Individual stereoisomers of compounds are prepared by synthesis from optically active starting materials containing the desired chiral centers or by preparation of mixtures of enantiomeric products followed by separation, such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, use of chiral resolving agents, or direct separation of the enantiomers on chiral chromatographic columns.
- Starting compounds of particular stereochemistry are either commercially available or are made by the methods described below and resolved by techniques well-known in the art.
- This alcohol is reacted with a silyl enol ether derived from ethyl pyruvate, in the presence of a Lewis acid such as stannic chloride, in a suitable solvent such as methylene chloride at about -78°C to -50°C to provide the ketoester intermediate bearing R 1 , R 2 , and R 3 (III).
- a Lewis acid such as stannic chloride
- a suitable solvent such as methylene chloride
- reaction mixture was diluted with methylene chloride (50 mL), washed with two 50 mL portions of water, dried over anhydrous sodium sulfate, and concentrated in vacuo to give l-bromo-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-one as a light brown liquid (80%) which was used for the next reaction without further purification.
- xvii 2-cyclopentylmethyl-4-(2,3-dihydro-benzofuran-7-yl)-2-hydroxy-4- methylpentanoic acid (l-oxo-l,3-dihydroisobenzofuran-5-yl)amide; xviii: 2-cyclo ⁇ entylmethyl-4-(2,3-dihydro-benzofuran-7-yl)-2-hydroxy-4- methylpentanoic acid (4-methyl- 1 -oxo- lH-benzo[d] [ 1 ,2]oxazin-6-yl)amide;
- xxvii 4-benzofuran-7-yl-2-cyclohexylmethyl-2-hydroxy-4-methylpentanoic acid (1- oxo- 1 , 3 -dihydroisobenzofuran-5 -yl)amide; xxviii: 4-benzofuran-7-yl-2-cyclohexylmethyl-2-hydroxy-4-methylpentanoic acid (4- methyl-1 -oxo-lH-benzo[d][l ,2]oxazin-6-yl)amide;
- xxxii 4-benzofuran-7-yl-2-cyclopentyl-2-hydroxy-4-methylpentanoic acid (4-methyl- 1- oxo-lH-benzo[d][l,2]oxazin-6-yl)amide;
- xxxvii 2-benzyl-4-(5-chloro-2-methoxyphenyl)-2-hydroxy-4-methylpentanoic acid (1- oxo-l,3-dihydroisobenzofuran-5-yl)amide; xxxviii: 2-benzyl-4-(5-chloro-2-methoxyphenyl)-2-hydroxy-4-methylpentanoic acid (4- methyl- 1 -oxo- lH-benzo[d] [ 1 ,2]oxazin-6-yl)amide;
- xxxix 4-(5-chloro-2-methoxyphenyl)-2-cyclohexylmethyl-2-hydroxy-4-methylpentanoic acid (l-oxo-l,3-dihydroisobenzofuran-5-yl)amide;
- xxxxvii 2-(2-chlorobenzyl)-4-(5-chloro-2-methoxyphenyl)-2-hydroxy-4-methylpentanoic acid (l-oxo-l,3-dihydroisobenzofuran-5-yl)amide; and xxxxviii: 2-(2-chlorobenzyl)-4-(5-chloro-2-methoxyphenyl)-2-hydroxy-4- methylpentanoic acid (4-methyl- 1 -oxo- lH-benzo[d][l ,2]oxazin-6-yl)amide.
- An example of such a probe is rhodamine (TAMRA)-labeled dexamethasone.
- the affinity of the probe for the steroid receptor was then determined in a titration experiment.
- the fluorescence polarization value of the probe in assay buffer was measured on an SLM-8100 fluorometer using the excitation and emission maximum values described above. Aliquots of expression vector lysate were added and fluorescence polarization was measured after each addition until no further change in polarization value was observed. Non-linear least squares regression analysis was used to calculate the dissociation constant of the probe from the polarization values obtained for lysate binding to the probe.
- This assay uses fluorescence polarization (FP) to quantitate the ability of test compounds to compete with tettamethyl rhodamine (TAMRA)-labeled dexamethasone for binding to a human glucocorticoid receptor (GR) complex prepared from an insect expression system.
- the assay buffer was: 10 mM TES, 50 mM KC1, 20 mM Na 2 Mo0 4 -2H 2 0, 1.5 mM EDTA, 0.04%) w/v CHAPS, 10%) v/v glycerol, 1 mM dithiothreitol, pH 7.4.
- Test compounds were dissolved to 1 mM in neat DMSO and then further diluted to lOx assay concentration in assay buffer supplemented with 10% v/v DMSO. Test compounds were serially diluted at lOx assay concentrations in 10% DMSO-containing buffer in 96-well polypropylene plates. Binding reaction mixtures were prepared in 96-well black Dynex microtiter plates by sequential addition of the following assay components to each well: 15 ⁇ L of lOx test compound solution, 85 ⁇ L of GR-containing baculovirus lysate diluted 1:170 in assay buffer, and 50 ⁇ L of 15 nM TAMRA-labeled dexamethasone.
- Positive controls were reaction mixtures containing no test compound; negative conttols (blanks) were reaction mixtures containing 0.7 ⁇ M to 2 ⁇ M dexamethasone.
- the binding reactions were incubated for 1 hour at room temperature and then read for fluorescence polarization in the LJL Analyst set to 550 nm excitation and 580 nm emission, with the Rhodamine 561 dichroic minor installed.
- IC 50 values were determined by iterative non-linear curve fitting of the FP signal data to a 4-parameter logistic equation.
- PR progesterone receptor
- ER estrogen receptor
- mineralocorticoid receptors to evaluate the compound's selectivity for GR.
- PR insect cell lysate is diluted 1:7.1 and MR lysate diluted 1 :9.4.
- PR probe is TAMRA-labeled mifepristone, used at a final concentration of 5 nM in the assay, and the negative controls (blanks) were reactions containing mifepristone at 0.7 ⁇ M to 2 ⁇ M.
- the ER protocol is similar to the above protocols, but uses PanVera kit receptor, fluorescein-labeled probe.
- the assay components are made in the same volumes as above, to produce final assay concentrations for ER of 15 nM and ES2 probe of 1 nM.
- the component order of addition is modified from the above assays: probe is added to the plate first, followed by receptor and test compound.
- the plates are read in the LJL Analyst set to 485 nm excitation and 530 nm emission, with the Fluorescein 505 dichroic minor installed.
- Compounds found to bind to the glucocorticoid receptor may be evaluated for dissociation of transactivation and transrepression by assays cited in the Background of the Invention (CM. Bamberger and H.M. Schulte, Eur. J. Clin. Invest., 2000, 30 (suppl. 3) 6-9) or by the assays described below.
- Aromatase in Fibroblasts (Cell Assay for Transactivation)
- Dexamethasone a synthetic ligand to the glucocorticoid receptor (GR) induces expression of aromatase in human foreskin fibroblast cells.
- the activity of aromatase is measured by the conversion of testosterone to estradiol in culture media.
- Compounds that exhibit binding to GR are evaluated for their ability to induce aromatase activity in human foreskin fibroblasts.
- Human foreskin fibroblast cells (ATCC Cat. No. CRL-2429, designation CCD112SK) are plated on 96 well plates at 50,000 cells per well 5 days before use, in Iscove's Modified Dulbecco's Media (GibcoBRL Life Technologies Cat No. 12440-053) supplemented with 10% charcoal filtered FBS (Clonetech Cat No. SH30068) and Gentamycin (GibcoBRL Life Technologies Cat. No. 15710-064). On the day of the experiment, the media in the wells is replaced with fresh media. Cells are treated with test compounds to final concentrations of 10 "5 M to 10 "8 M, and testosterone to a final concentration of 300 ng/mL.
- Control wells include: (a) wells that receive testosterone only, and (b) wells that receive testosterone plus 2 ⁇ M of dexamethasone to provide maximum induction of aromatase. Plates are incubated at 37°C overnight (15 to 18 hours), and supematants are harvested at the end of incubation. Estradiol in the supernatant is measured using ELISA kits for estradiol (made by ALPCO, obtained from American Laboratory Products Cat. No. 020-DR-2693) according to the manufacture's instruction. The amount of estradiol is inversely proportional to the ELISA signals in each well.
- test compounds The extent of aromatase induction by test compounds is expressed as a relative percentage to dexamethasone. EC 50 values of test compounds are derived by non-linear curve fitting. 2. Inhibition of IL-6 Production in Fibroblasts (Cell Assay for Transrepression)
- Human foreskin fibroblast cells produce IL-6 in response to stimulation by pro- inflammatory cytokine IL-1.
- This inflammatory response as measured by the production of IL-6, can be effectively inhibited by dexamethasone, a synthetic ligand to the glucocorticoid receptor (GR).
- GR glucocorticoid receptor
- Human foreskin fibroblast cells (ATCC Cat. No. CRL-2429) are plated on 96 well plates at 5,000 cells per well the day before use, in Iscove's Modified Dulbecco's Media (GibcoBRL Life Technologies Cat. No. 12440-053) supplemented with 10% charcoal filtered FBS (Clonetech Cat. No. SH30068) and Gentamycin (GibcoBRL Life Technologies Cat. No. 15710-064). On the next day, media in the wells is replaced with fresh media. Cells are treated with IL-1 (rhIL-l ⁇ , R&D Systems Cat. No.
- test compounds 200-LA to a final concentration of 1 ng/mL, and with test compounds to final concentrations of 10 "5 M to 10 "8 M, in a total volume of 200 ⁇ L per well.
- Samples are done in duplicates. Background control wells do not receive test compounds or IL-1. Positive control wells receive IL-1 only and represent maximum (or 100%) amount of IL-6 production. Plates are incubated at 37°C overnight (15 to 18 hours), and supematants are harvested at the end of incubation. IL-6 levels in the supematants are determined by the ELISA kits for IL-6 (MedSystems Diagnostics GmbH, Vienna, Austria, Cat. No. BMS213TEN) according to manufacture's instructions. The extent of inhibition of IL-6 by test compounds is expressed in percentage relative to positive controls. ICso values of test compounds are derived by non-linear curve fitting.
- Evaluation of agonist or antagonist activity of c ompounds binding to the glucocorticoid receptor may be determined by any of the assays.
- TAT Tyrosine Aminotransf erase
- the hepatoma cells were pre-stimulated by addition of dexamethasone (concentration ranges from 3 x 10 "9 M to 3 x 10 "8 M) shortly before the test compound was applied to the cells.
- dexamethasone concentration ranges from 3 x 10 "9 M to 3 x 10 "8 M
- the steroidal non-selective GR/PR antagonist mifepristone was used as control.
- HeLa cells were stably co-transfected with the pHHLuc-plasmid containing a fragment of the MMTV-LTR (-200 to +100 relative to the transcription start site) cloned in front of the luciferase gene (Norden, 1988) and the pcDNA3.1 plasmid (Invitrogen) constitutively expressing the resistance for the selective antibiotic GENETICIN®. Clones with best induction of the MMTV-promoter were selected and used for further experiments.
- the MMTV-promoter was pre-stimulated by adding dexamethasone (3 x 10 "9 M to 3 x 10 "8 M) shortly before the test compound was applied to the cells.
- dexamethasone 3 x 10 "9 M to 3 x 10 "8 M
- the steroidal non-selective GR/PR antagonist mifepristone was used as control.
- U-937 cells were incubated for 2 to 4 days in RPMI1640 medium containing 10% CCS (charcoal treated calf serum). The cells were transfened to 96 well plates (40,000 cells/100 ⁇ L/well) and stimulated with 1 ⁇ g/mL LPS (dissolved in PBS) in the presence or absence of dexamethasone or test compound (dissolved in DMSO, final concentration 0.2%). Control cells were treated with 0.2% DMSO. After 18 hours, the IL-8 concentration in the cell supernatant was measured by ELISA, using the "OptEIA human IL-8 set" (Pharmingen, Cat. No. 2654KI).
- the LPS-induced IL-8 secretion was inhibited by adding dexamethasone (3 x 10 " M to 3 x 10 " M) shortly before the test compound was applied to the cells.
- dexamethasone 3 x 10 " M to 3 x 10 " M
- the steroidal non-selective GR PR antagonist mifepristone was used as control.
- HeLa cells were stably co-transfected with a plasmid containing a 1.3 kb fragment of the human I CAM-promoter (-1353 to -9 relative to the transcription start site, Ledebur and Parks, 1995) cloned in front of the luciferase gene and the pcDNA3.1 plasmid (Invitrogen) which constitutively expresses the resistance for the antibiotic GENETICIN®. Clones with best induction of the ICAM-promoter were selected and used for further experiments. Cells were transfened to 96 well plates (15,000 cells/100 ⁇ L/well) in DMEM medium supplemented with 3% CCS.
- the activation of the ICAM-promoter was induced by addition of 1 0 ng/mL recombinant TNF-alpha ( R&D System, Cat. No. 210-TA). Simultaneously the cells were treated with the test compound or dexamethasone (dissolved in DMSO, final concentration 0.2%). Control cells were treated with DMSO only. After 18 hours, the cells were lysed with cell lysis reagent (Promega, Cat. No. E1531), luciferase assay reagent (Promega, Cat. No. E1501) was added and glow luminescence was measured using a luminometer (BMG, Offenburg).
- the TNF-alpha-induced activation of the ICAM- promoter was inhibited by adding dexamethasone (3 x 10 "9 M to 3 x 10 "8 M) shortly before the test compound was applied to the cells.
- dexamethasone 3 x 10 "9 M to 3 x 10 "8 M
- the steroidal non-selective GR PR antagonist mifepristone was used as control.
- the prefened potency range in the above assays is between 0.1 nM and 10 ⁇ M, the more preferred potency range is 0.1 nM to 1 ⁇ M, and the most prefened potency range is 0.1 nM to 100 nM.
- Representative compounds of the invention have been tested and have shown activity as modulators of the glucocorticoid receptor function in one or more of the above assays.
- the following compounds of the invention have demonstrated potent activity in the GR binding assay:
- the invention also provides methods of modulating the glucocorticoid receptor function in a patient comprising administering to the patient a compound according to the invention. If the pu ⁇ ose of modulating the glucocorticoid receptor function in a patient is to treat a disease-state or condition, the administration preferably comprises a therapeutically or pharmaceutically effective amount of a pharmaceutically acceptable compound according to the invention.
- the administration preferably comprises an effective amount of a compound according to the invention, that is, the amount necessary to obtain the desired effect or degree of modulation.
- the compounds of the invention are useful in modulating the glucocorticoid receptor function. In doing so, these compounds have therapeutic use in treating disease-states and conditions mediated by the glucocorticoid receptor function or that would benefit from modulation of the glucocorticoid receptor function.
- the compounds of the invention modulate the glucocorticoid receptor function, they have very useful anti-inflammatory and antiallergic, immune-suppressive, and anti- proliferative activity and they can be used in patients as dmgs, particularly in the form of pharmaceutical compositions as set forth below, for the treatment of disease-states and conditions.
- the agonist compounds according to the invention can be used in patients as dmgs for the treatment of the following disease-states or indications that are accompanied by inflammatory, allergic, and/or proliferative processes:
- Lung diseases chronic, obstructive lung diseases of any genesis, particularly bronchial asthma and chronic obstructive pulmonary disease (COPD); adult respiratory distress syndrome (ARDS); bronchiectasis; bronchitis of various genesis; all forms of restrictive lung diseases, particularly allergic alveolitis; all forms of lung edema, particularly toxic lung edema; all forms of interstitial lung diseases of any genesis, e.g., radiation pneumonitis; and sarcoidosis and granulomatoses, particularly Boeck disease;
- Rheumatic diseases or autoimmune diseases or joint diseases all forms of rheumatic diseases, especially rheumatoid arthritis, acute rheumatic fever, and polymyalgia rheumatica; reactive arthritis; rheumatic soft tissue diseases; inflammatory soft tissue diseases of other genesis; arthritic symptoms in degenerative joint diseases (arthroses); traumatic arthritis; collagenoses of any genesis, e.g., systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, Sj ⁇ gren syndrome, Still disease, and Felty syndrome;
- Allergic diseases all forms of allergic reactions, e.g., angioneurotic edema, hay fever, insect bites, allergic reactions to dmgs, blood derivatives, c ontrast agents, etc., anaphylactic shock (anaphylaxis), urticaria, angioneurotic edema, and contact dermatitis;
- Vasculitis diseases panarteritis nodosa, polyarteritis nodosa, arteritis temporal [i: s. Wegner granulomatosis, giant cell arthritis, and erythema nodosum;
- Dermatological diseases atopic dermatitis, particularly in children; psoriasis; pityriasis rubra pilaris; erythematous diseases triggered by various noxa, e.g., rays, chemicals, bums, etc.; bullous dermatoses; diseases of the lichenoid complex; pruritus (e.g., of allergic genesis); sebonheic dermatitis; rosacea; pemphigus vulgaris; erythema multiforme exudativum; balanitis; vulvitis; hair loss, such as occurs in alopecia areata; and cutaneous T cell lymphomas;
- Renal diseases nephrotic syndrome; and all types of nephritis, e.g., glomerulonephritis;
- Hepatic diseases acute liver cell disintegration; acute hepatitis of various genesis, e.g., viral, toxic, drug-induced; and chronically aggressive and/or chronically intermittent hepatitis;
- Gastrointestinal diseases inflammatory bowel diseases, e.g., regional enteritis (Crohn disease), colitis ulcerosa; gastritis; peptic esophagitis (refluxoesophagitis); and gastroenteritis of other genesis, e.g., nontropical sprue;
- Proctological diseases anal eczema; fissures; hemonhoids; and idiopathic proctitis;
- Neurological diseases brain edema, particularly tumor-related brain edema; multiple sclerosis; acute encephalomyelitis; meningitis; acute spinal cord injury; stroke; and various forms of seizures, e.g., nodding spasms;
- Tumor diseases acute lymphatic leukemia; malignant lymphoma; lymphogranulomatoses; lymphosarcoma; extensive metastases, particularly in mammary, bronchial, and prostatic carcinoma;
- Endocrine diseases endocrine ophthalmopathy; endocrine orbitopathia; thyrotoxic crisis; Thyroiditis de Quervain; Hashimoto thyroiditis; Morbus Basedow; granulomatous thyroiditis; struma lymphomatosa; and Grave disease;
- various other disease-states or conditions including type I diabetes (insulin- dependent diabetes), osteoarthritis, Guillain-Bane syndrome, restenosis following percutaneous transluminal coronary angioplasty, Alzheimer disease, acute and chronic pain, atherosclerosis, reperfusion injury, bone reso ⁇ tion diseases, congestive heart failure, myocardial infarction, thermal injury, multiple organ injury secondary to trauma, acute purulent meningitis, necrotizing enterocolitis and syndromes associated with hemodialysis, leukopheresis, and granulocyte transfusion.
- the compounds according to the invention can be used for the treatment of any other disease-states or conditions not mentioned above which have been treated, are treated, or will be treated with synthetic glucocorticoids (see, e.g., HJ. Hatz, Glucocorticoide: Immunologische Gmndlagen. Pharmakologie und Therapierichtlimen [Glucocorticoids: Immunological Fundamentals, Pharmacology, and Therapeutic Guidelines], Stuttgart: Verlagsgesellschaft mbH, 1998, which is hereby inco ⁇ orated by reference in its entirety). Most or all of the indications (i) through (xx) mentioned above are described in detail in H.J. Hatz, Glucocorticoide: Immunologische Gmndlagen, Pharmakologie und Therapierichtlimen. Furthermore, the compounds of the invention can also be used to treat disorders other than those listed above or mentioned or discussed herein, including in the Background of the Invention.
- the antagonist compounds according to the invention can be used in patients as dmgs for the treatment of the following disease- states or indications, without limitation: type II diabetes (non-insulin-dependent diabetes); obesity; cardiovascular diseases; hypertension; arteriosclerosis; neurological diseases, such as psychosis and depression; adrenal and pituitary tumors; glaucoma; and Cushing syndrome based on an ACTH-secreting tumor like pituitary adenoma.
- the compounds of the invention are useful for treating obesity and all disease-states and indications related to a deregulated fatty acids metabolism such as hypertension, atherosclerosis, and other cardiovascular diseases.
- the antagonist compounds of the invention are useful in treating all disease-states and conditions that involve increased carbohydrate, protein, and lipid metabolism and would include disease-states and conditions leading to catabolism like muscle frailty (as an example of protein metabolism).
- the compounds of the invention may also be used in diagnostic applications and for commercial and other pu ⁇ oses as standards in competitive binding assays.
- the compounds of the invention may be used in the form of the compounds themselves or they may be modified by attaching a radioisotope, luminescence, fluorescent label or the like in order to obtain a radioisotope, luminescence, or fluorescent probe, as would be known by one of skill in the art and as outlined in Handbook of Fluorescent Probes and Research Chemicals, 6th Edition, R.P. Haugland (ed.), Eugene: Molecular Probes, 1996; Fluorescence and Luminescence Probes for Biological A ctivitv. W.T.
- the compounds of the invention are typically administered in the form of a pharmaceutical composition.
- Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the invention.
- the compounds of the invention may also be administered alone or in combination with adjuvants that enhance stability of the compounds of the invention, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increased inhibitory activity, provide adjunct therapy, and the like.
- the compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances.
- the compounds of this invention are administered in a therapeutically or phannaceutically effective amount, but may be administered in lower amounts for diagnostic or other pu ⁇ oses.
- administration can be, for example, orally, buccally (e.g., sublingually), nasally, parenterally, topically, transdermally, vaginally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
- the pharmaceutical compositions will generally include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, caniers, adjuvants, diluents, vehicles, or combinations thereof.
- Such pharmaceutically acceptable excipients, carriers, or additives as well as methods of making pharmaceutical compositions for various modes or administration are well-known to those of skill in the art. The state of the art is evidenced, e.g., by Remington: The Science and Practice of Pharmacy. 20th Edition, A. Gennaro (ed.), Lippincott Williams & Wilkins, 2000; Handbook of Pharmaceutical Additives, Michael & Irene Ash (eds.), Gower, 1995; Handbook of Pharmaceutical Excipients.
- the forms of the compounds of the invention utilized in a particular pharmaceutical formulation will be selected (e.g., salts) that possess suitable physical characteristics (e.g., water solubility) that is required for the formulation to be efficacious.
- compositions suitable for buccal (sub-lingual) administration include lozenges comprising a compound of the present invention in a flavored base, usually sucrose, and acacia or tragacanth, and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
- compositions suitable for parenteral administration comprise sterile aqueous preparations of a compound of the present invention. These preparations are preferably administered intravenously, although administration can also be effected by means of subcutaneous, intramuscular, or intradermal injection.
- injectable pharmaceutical formulations are commonly based upon injectable sterile saline, phosphate-buffered saline, oleaginous suspensions, or other injectable caniers known in the art and are generally rendered sterile and isotonic with the blood.
- the injectable pharmaceutical formulations may therefore be provided as a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, including 1,3-butanediol, water, Ringer's solution, isotonic sodium chloride solution, fixed oils such as synthetic mono- or diglycerides, fatty acids such as oleic acid, and the like.
- a nontoxic parenterally acceptable diluent or solvent including 1,3-butanediol, water, Ringer's solution, isotonic sodium chloride solution, fixed oils such as synthetic mono- or diglycerides, fatty acids such as oleic acid, and the like.
- injectable pharmaceutical formulations are formulated according to the known art using suitable dispersing or setting agents and suspending agents.
- Injectable compositions will generally contain from 0.1 to 5% w/w of a compound of the invention.
- Solid dosage forms for oral administration of the compounds include capsules, tablets, pills, powders, and granules.
- a pharmaceutically acceptable composition containing a compound(s) of the invention is formed by the inco ⁇ oration of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, pregelatinized starch, magnesium stearate, sodium saccharine, talcum, cellulose ether derivatives, glucose, gelatin, sucrose, citrate, propyl gallate, and the like.
- excipients such as, for example, pharmaceutical grades of mannitol, lactose, starch, pregelatinized starch, magnesium stearate, sodium saccharine, talcum, cellulose ether derivatives, glucose, gelatin, sucrose, citrate, propyl gallate, and the like.
- Such solid pharmaceutical formulations may include formulations, as are well known in the art, to provide prolonged or sustained delivery of the dmg to the gastrointestinal tract by any number of mechanisms, which include, but are not limited to, pH sensitive release from the dosage form based on the changing pH of the small intestine, slow erosion of a tablet or capsule, retention in the stomach based on the physical properties of the formulation, bioadhesion of the dosage form to the mucosal lining of the intestinal tract, or enzymatic release of the active dmg from the dosage form.
- Liquid dosage forms for oral administration of the compounds include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs, optionally containing pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like. These compositions can also contain additional adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.
- a carrier such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like.
- additional adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.
- Topical dosage forms of the compounds include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, eye ointments, eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist dmg penetration and emollients in ointments and creams. Topical application may be once or more than once per day depending upon the usual medical considerations. Furthermore, prefened compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles.
- the formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation, more usually they will form up to about 80% of the formulation.
- Transdermal administration is also possible.
- Pharmaceutical compositions suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
- the dosage administration will, of course, b e c ontinuous rather than intermittent throughout the dosage regimen.
- patches suitably contain a compound of the invention in an optionally buffered, aqueous solution, dissolved and/or dispersed in an adhesive, or dispersed in a polymer.
- a suitable concentration of the active compound is about 1% to 35%, preferably about 3% to 15%.
- the compounds of the invention are conveniently delivered in the form of an aerosol spray from a pump spray device not requiring a propellant gas or from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide, or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide, or other suitable gas.
- the aerosol spray dosage unit may be determined by providing a valve to deliver a metered amount so that the resulting metered dose inhaler (MDI) is used to administer the compounds of the invention in
- Such inhaler, nebulizer, or atomizer devices are known in the art, for example, in PCT International Publication Nos. WO 97/12687 (particularly Figure 6 thereof, which is the basis for the commercial RESPIMAT® nebulizer); WO 94/07607; WO 97/12683; and WO 97/20590, to which reference is hereby made and each of which is inco ⁇ orated herein by reference in their entireties.
- Rectal administration can be effected utilizing unit dose suppositories in which the compound is admixed with low-melting water-soluble or insoluble solids such as fats, cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights, or fatty acid esters of polyethylene glycols, or the like.
- the active compound is usually a minor component, often from about 0.05 to 10% by weight, with the remainder being the base component.
- the compounds of the invention are formulated with an acceptable carrier or excipient.
- the carriers or excipients used must, of course, be acceptable in the sense of being compatible with the other ingredients of the composition and must not be deleterious to the patient.
- the carrier or excipient can be a solid or a liquid, or both, and is preferably formulated with the compound of the invention as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compound.
- Such carriers or excipients include inert fillers or diluents, binders, lubricants, disintegrating agents, solution retardants, reso ⁇ tion accelerators, abso ⁇ tion agents, and coloring agents.
- Suitable binders include starch, gelatin, natural sugars such as glucose or ⁇ -lactose, com sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
- Lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
- Disintegrators include starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
- a therapeutically effective daily dose is from about 0.001 mg to about 15 mg/kg of body weight per day of a compound of the invention; preferably, from about 0.1 mg to about 10 mg/kg of body weight per day; and most preferably, from about 0.1 mg to about 1.5 mg/kg of body weight per day.
- the dosage range would be from about 0.07 mg to about 1050 mg per day of a compound of the invention, preferably from about 7.0 mg to about 700 mg per day, and most preferably from about 7.0 mg to about 105 mg per day.
- compositions encompass all the foregoing additives and the like.
- the finely ground active substance, lactose, and some of the com starch are mixed together.
- the mixture is screened, then moistened with a solution of polyvinylpynolidone in water, kneaded, wet-granulated and dried.
- the granules, the remaining com starch and the magnesium stearate are screened and mixed together.
- the mixture is compressed to produce tablets of suitable shape and size.
- the finely ground active substance, some of the com starch, lactose, microcrystalline cellulose, and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining com starch and water to form a granulate which is dried and screened.
- the sodium-carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
- the active substance, com starch, lactose, and polyvinylpynolidone are thoroughly mixed and moistened with water.
- the moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45 °C and the granules are then passed through the same screen.
- convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine.
- the tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc.
- the finished coated tablets are polished with wax.
- the substance and co starch are mixed and moistened with water.
- the moist mass is screened and dried.
- the dry granules are screened and mixed with magnesium stearate.
- the finished mixture is packed into size 1 hard gelatine capsules.
- the active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic.
- the solution obtained is filtered free from pyrogens and the filtrate is fransfened under aseptic conditions into ampoules which are then sterilized and sealed by fusion.
- the ampoules contain 5 mg, 25 mg, and 50 mg of active substance.
- the hard fat is melted. At 40°C, the ground active substance is homogeneously dispersed therein. The mixture is cooled to 38°C and poured into slightly chilled suppository molds.
- the suspension is fransfened into a conventional aerosol container with a metering valve. Preferably, 50 ⁇ L of suspension are delivered per spray.
- the active substance may also be metered in higher doses if desired (e.g., 0.02% by weight).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60309829T DE60309829T2 (en) | 2002-01-14 | 2003-01-03 | GLUCOCORTICOIDMIMETICS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND THEIR USES |
AU2003202216A AU2003202216A1 (en) | 2002-01-14 | 2003-01-03 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
CA002472746A CA2472746A1 (en) | 2002-01-14 | 2003-01-03 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
JP2003560002A JP2005519897A (en) | 2002-01-14 | 2003-01-03 | Glucocorticoid mimetics, method for producing the same, pharmaceutical preparation containing the same, and use thereof |
EP03701228A EP1467982B8 (en) | 2002-01-14 | 2003-01-03 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34848602P | 2002-01-14 | 2002-01-14 | |
US60/348,486 | 2002-01-14 | ||
US37907802P | 2002-05-09 | 2002-05-09 | |
US60/379,078 | 2002-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003059899A1 true WO2003059899A1 (en) | 2003-07-24 |
Family
ID=26995749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/000300 WO2003059899A1 (en) | 2002-01-14 | 2003-01-03 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (2) | US6960581B2 (en) |
EP (1) | EP1467982B8 (en) |
JP (1) | JP2005519897A (en) |
AT (1) | ATE346058T1 (en) |
AU (1) | AU2003202216A1 (en) |
CA (1) | CA2472746A1 (en) |
DE (1) | DE60309829T2 (en) |
ES (1) | ES2276038T3 (en) |
WO (1) | WO2003059899A1 (en) |
Cited By (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005003098A1 (en) * | 2003-07-01 | 2005-01-13 | Schering Aktiengesellschaft | Heterocyclically substituted pentanol derivatives, method for the production thereof, and use thereof as anti-inflammatory agents |
WO2005005452A1 (en) | 2003-07-11 | 2005-01-20 | Glaxo Group Limited | Specific glucocorticosteroid compound having anti- inflammatory activity |
WO2005030213A1 (en) | 2003-09-24 | 2005-04-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo |
WO2005040145A1 (en) * | 2003-10-16 | 2005-05-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols |
WO2005095401A1 (en) * | 2004-03-22 | 2005-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics |
WO2005116037A1 (en) | 2004-05-24 | 2005-12-08 | Glaxo Group Limited | Purine derivative |
WO2006104889A2 (en) | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Novel compounds |
WO2006135826A1 (en) * | 2005-06-10 | 2006-12-21 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE102005030293A1 (en) * | 2005-06-24 | 2007-01-04 | Schering Ag | Use of nonsteroidal progesterone receptor modulators |
DE102005030294A1 (en) * | 2005-06-24 | 2007-01-04 | Schering Ag | Nonsteroidal progesterone receptor modulators |
WO2007009757A1 (en) | 2005-07-19 | 2007-01-25 | Glaxo Group Limited | Purine derivatives as agonists of the adenosine a2a receptor |
JP2007529424A (en) * | 2004-03-13 | 2007-10-25 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 2-Propanol derivatives and 2-propylamine derivatives and their use as glucocorticoid ligands |
WO2007122165A1 (en) | 2006-04-20 | 2007-11-01 | Glaxo Group Limited | Novel compounds |
WO2007144327A2 (en) | 2006-06-12 | 2007-12-21 | Glaxo Group Limited | Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands |
WO2008027796A2 (en) | 2006-08-31 | 2008-03-06 | Bausch & Lomb Incorporated | Compositions and methods for treating or preventing glaucoma or progression thereof |
WO2008043789A1 (en) * | 2006-10-13 | 2008-04-17 | Glaxo Group Limited | Novel compounds |
WO2008070507A2 (en) * | 2006-12-06 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2008077647A2 (en) * | 2006-12-21 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Alpha- amino alcohols as non-steroidal progesterone receptor modulators |
US7408060B2 (en) | 2005-06-24 | 2008-08-05 | Schering Ag | Nonsteroidal progesterone receptor modulators |
WO2008118724A1 (en) | 2007-03-23 | 2008-10-02 | Smithkline Beecham Corporation | Indole carboxamides as ikk2 inhibitors |
DE102007058747A1 (en) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nonsteroidal progesterone receptor modulators |
US7579335B2 (en) | 2005-01-10 | 2009-08-25 | Glaxo Group Limited | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
US7579469B2 (en) * | 2003-01-03 | 2009-08-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2009147187A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
EP2157087A1 (en) | 2005-12-20 | 2010-02-24 | Glaxo Group Limited | 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders |
WO2010068311A1 (en) | 2008-05-23 | 2010-06-17 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein inhibitor |
US7741361B2 (en) | 2004-12-27 | 2010-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
WO2010102958A1 (en) | 2009-03-09 | 2010-09-16 | Glaxo Group Limited | 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107955A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING |
WO2010106016A1 (en) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010122089A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | N-pyrazolyl carboxamides as crac channel inhibitors |
WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
US7932392B2 (en) | 2002-03-26 | 2011-04-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
WO2011067366A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
US7968577B2 (en) | 2006-11-01 | 2011-06-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
WO2011084316A2 (en) | 2009-12-16 | 2011-07-14 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
WO2011134971A1 (en) | 2010-04-29 | 2011-11-03 | Glaxo Group Limited | 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors |
WO2012032065A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
WO2012032067A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
EP2436697A1 (en) | 2004-07-01 | 2012-04-04 | Glaxo Group Limited | Chimeric and humanised monoclonal antibodies against interleukin-13 |
EP2436686A1 (en) | 2005-03-25 | 2012-04-04 | Glaxo Group Limited | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator |
WO2012052458A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
WO2012055846A1 (en) | 2010-10-27 | 2012-05-03 | Glaxo Group Limited | Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5- { [4-(1-methylethyl)-1-pi perazinyl] methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders |
US8268859B2 (en) | 2008-06-06 | 2012-09-18 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
WO2012123312A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
WO2012123311A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk) |
WO2012170175A1 (en) * | 2011-06-07 | 2012-12-13 | Bausch & Lomb Incorporated | Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain |
WO2015042078A2 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
WO2015055690A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
WO2015055691A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
EP2899191A1 (en) | 2009-04-30 | 2015-07-29 | Glaxo Group Limited | Oxazole substituted indazoles as pi3-kinase inhibitors |
WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
WO2017137535A1 (en) | 2016-02-12 | 2017-08-17 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as inhibitors of kinase activity |
WO2018029126A1 (en) | 2016-08-08 | 2018-02-15 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
EP3312164A1 (en) | 2014-03-28 | 2018-04-25 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
WO2018192864A1 (en) | 2017-04-18 | 2018-10-25 | Glaxosmithkline Intellectual Property Development Limited | Oxepinopyrazole derivatives as inhibitors of pi3-kinase activity |
WO2019020657A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridine-3-sulfonamide compounds as pi3-kinase inhibitors |
WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
WO2019143874A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
WO2021191875A1 (en) | 2020-03-26 | 2021-09-30 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60309829T2 (en) | 2002-01-14 | 2007-09-13 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | GLUCOCORTICOIDMIMETICS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND THEIR USES |
US7268152B2 (en) * | 2002-03-26 | 2007-09-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7186864B2 (en) * | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) * | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
AU2003259747A1 (en) | 2002-08-21 | 2004-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
RS20050174A (en) * | 2002-08-29 | 2007-06-04 | Boehringer Ingelheim Pharmaceuticals Inc., | -3(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases |
US20040224992A1 (en) * | 2003-02-27 | 2004-11-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US20050090559A1 (en) * | 2003-07-01 | 2005-04-28 | Markus Berger | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
EP1960351B1 (en) * | 2005-12-09 | 2013-06-19 | F.Hoffmann-La Roche Ag | Propionamide compounds as antiinflammatory agents |
KR20090033865A (en) * | 2006-07-07 | 2009-04-06 | 보오슈 앤드 롬 인코포레이팃드 | Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye |
AU2007284175A1 (en) * | 2006-08-07 | 2008-02-21 | Bausch & Lomb Incorporated | Treating infections and sequelae thereof with combined dissociated' glucocorticoid receptor agonists and anti-infective agents |
US20110104159A1 (en) * | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
CN101553214B (en) * | 2006-09-11 | 2012-12-26 | 博士伦公司 | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
US20110105559A1 (en) * | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy |
US20090042936A1 (en) * | 2007-08-10 | 2009-02-12 | Ward Keith W | Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation |
US20090087443A1 (en) | 2007-09-27 | 2009-04-02 | Bartels Stephen P | Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery |
WO2009069736A1 (en) * | 2007-11-28 | 2009-06-04 | Kyowa Hakko Kirin Co., Ltd. | Nitrogenated compound |
US20090239836A1 (en) * | 2008-03-24 | 2009-09-24 | Mary Lee Ciolkowski | Multifunctional Ophthalmic Compositions |
US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
US20110077270A1 (en) * | 2009-04-21 | 2011-03-31 | Pfeffer Bruce A | Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure |
US20100312013A1 (en) | 2009-06-03 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Steroselective synthesis of certain trifluoromethyl-substituted alcohols |
US20110130567A1 (en) | 2009-06-03 | 2011-06-02 | Boehringer Ingelheim International Gmbh | Steroselective synthesis of certain trifluoromethyl-substituted alcohols |
US20110130591A1 (en) | 2009-06-03 | 2011-06-02 | Boehringer Ingelheim International Gmbh | Steroselective synthesis of certain trifluoromethyl-substituted alcohols |
US20110130578A1 (en) | 2009-06-03 | 2011-06-02 | Boehringer Ingelheim International Gmbh | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols |
US9126997B1 (en) * | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0253503A2 (en) * | 1986-07-18 | 1988-01-20 | Imperial Chemical Industries Plc | Substituted anilides having antiandrogenic properties |
US4880839A (en) * | 1986-07-18 | 1989-11-14 | Imperial Chemical Industries Plc | Acyanilide derivatives |
DE19723722A1 (en) * | 1997-05-30 | 1998-12-10 | Schering Ag | Nonsteroidal progestogens |
US6323199B1 (en) * | 1998-11-27 | 2001-11-27 | Schering Aktiengesellschaft | Nonsteroidal anti-inflammatory agents |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8402755A (en) | 1983-09-22 | 1985-04-16 | Sandoz Ag | AZOLIC DERIVATIVES, METHOD FOR PREPARING THE SAME, PREPARATIONS CONTAINING THEM, AND USE THEREOF |
GB8406000D0 (en) | 1984-03-07 | 1984-04-11 | Ici Plc | Olefine derivatives |
US5039691A (en) * | 1989-06-08 | 1991-08-13 | Marion Merrell Dow Inc. | 5-(1-(imidazol)methyl)-3,3-disubstituted-2(3H)furanone derivatives |
CZ176197A3 (en) | 1994-12-22 | 1998-09-16 | Ligand Pharmaceuticals Incorporated | Modulators of steroidal receptors, processes of their preparation and use |
WO1997027852A1 (en) | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6506766B1 (en) * | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
BR9907788A (en) | 1998-02-13 | 2001-10-30 | Abbott Lab | Paraglycocorticoid selective anti-inflammatory agents |
AP1542A (en) * | 1999-04-30 | 2006-01-31 | Pfizer Prod Inc | Glucocorticoid receptor modulators. |
US6436986B1 (en) * | 1999-09-01 | 2002-08-20 | Abbott Laboratories | Glucocorticoid receptor antagonists for treatment of diabetes |
US6329534B1 (en) * | 1999-09-01 | 2001-12-11 | Abbott Laboratories | Glucocorticoid receptor antagonists for treatment of diabetes |
DE10038639A1 (en) * | 2000-07-28 | 2002-02-21 | Schering Ag | New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism |
US6583180B2 (en) * | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
ATE437853T1 (en) | 2001-02-14 | 2009-08-15 | Karobio Ab | GLUCOCORTICOID RECEPTORS MODULATORS |
DE60309829T2 (en) | 2002-01-14 | 2007-09-13 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | GLUCOCORTICOIDMIMETICS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND THEIR USES |
US7268152B2 (en) * | 2002-03-26 | 2007-09-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
MXPA04009329A (en) * | 2002-03-26 | 2005-01-25 | Boehringer Ingelheim Pharma | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof. |
US7186864B2 (en) * | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) * | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
RS20050174A (en) * | 2002-08-29 | 2007-06-04 | Boehringer Ingelheim Pharmaceuticals Inc., | -3(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases |
-
2003
- 2003-01-03 DE DE60309829T patent/DE60309829T2/en not_active Expired - Fee Related
- 2003-01-03 ES ES03701228T patent/ES2276038T3/en not_active Expired - Lifetime
- 2003-01-03 EP EP03701228A patent/EP1467982B8/en not_active Expired - Lifetime
- 2003-01-03 CA CA002472746A patent/CA2472746A1/en not_active Abandoned
- 2003-01-03 AU AU2003202216A patent/AU2003202216A1/en not_active Abandoned
- 2003-01-03 US US10/336,340 patent/US6960581B2/en not_active Expired - Lifetime
- 2003-01-03 JP JP2003560002A patent/JP2005519897A/en active Pending
- 2003-01-03 AT AT03701228T patent/ATE346058T1/en not_active IP Right Cessation
- 2003-01-03 WO PCT/US2003/000300 patent/WO2003059899A1/en active IP Right Grant
-
2005
- 2005-10-05 US US11/243,746 patent/US7189758B2/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0253503A2 (en) * | 1986-07-18 | 1988-01-20 | Imperial Chemical Industries Plc | Substituted anilides having antiandrogenic properties |
US4880839A (en) * | 1986-07-18 | 1989-11-14 | Imperial Chemical Industries Plc | Acyanilide derivatives |
DE19723722A1 (en) * | 1997-05-30 | 1998-12-10 | Schering Ag | Nonsteroidal progestogens |
US6323199B1 (en) * | 1998-11-27 | 2001-11-27 | Schering Aktiengesellschaft | Nonsteroidal anti-inflammatory agents |
Cited By (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8212040B2 (en) | 2002-03-26 | 2012-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof |
US7932392B2 (en) | 2002-03-26 | 2011-04-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7579469B2 (en) * | 2003-01-03 | 2009-08-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2005003098A1 (en) * | 2003-07-01 | 2005-01-13 | Schering Aktiengesellschaft | Heterocyclically substituted pentanol derivatives, method for the production thereof, and use thereof as anti-inflammatory agents |
US7288536B2 (en) | 2003-07-11 | 2007-10-30 | Glaxo Group Limited | Specific glucocorticosteroid compound having anti-inflammatory activity |
WO2005005451A1 (en) | 2003-07-11 | 2005-01-20 | Glaxo Group Limited | Specific glucocorticosteroid compound having anti- inflammatory activity |
US7638508B2 (en) | 2003-07-11 | 2009-12-29 | Glaxo Group Limited | Glucocorticosteroid compound having anti-inflammatory activity |
US7291609B2 (en) | 2003-07-11 | 2007-11-06 | Glaxo Group Limited | Specific glucocorticosteroid compound having anti-inflammatory activity |
US7524970B2 (en) | 2003-07-11 | 2009-04-28 | Glaxo Group Limited | Compounds |
WO2005005452A1 (en) | 2003-07-11 | 2005-01-20 | Glaxo Group Limited | Specific glucocorticosteroid compound having anti- inflammatory activity |
EP2380898A1 (en) | 2003-07-11 | 2011-10-26 | Glaxo Group Limited | Process to make glucocortisoid compounds |
WO2005030213A1 (en) | 2003-09-24 | 2005-04-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo |
JP2010209100A (en) * | 2003-09-24 | 2010-09-24 | Boehringer Ingelheim Pharmaceuticals Inc | Method for producing 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol derivative |
JP2007506750A (en) * | 2003-09-24 | 2007-03-22 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 1,1,1-trifluoro-4-phenyl-4-methyl-2- (1H-pyrrolo [2,3-c] pyridin-2-ylmethyl as a glucocorticoid ligand for the treatment of inflammatory diseases and diabetes ) Pentan-2-ol derivatives and related compounds |
KR101152690B1 (en) | 2003-09-24 | 2012-07-05 | 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 | 1,1,1-Trifluoro-4-phenyl-4-methyl-2-1H-pyrrolo[2,3-C]pyridin-2-ylmethylpentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes |
US8741897B2 (en) | 2003-09-24 | 2014-06-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
WO2005040145A1 (en) * | 2003-10-16 | 2005-05-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols |
US7507843B2 (en) | 2003-10-16 | 2009-03-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols |
JP2007529424A (en) * | 2004-03-13 | 2007-10-25 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 2-Propanol derivatives and 2-propylamine derivatives and their use as glucocorticoid ligands |
US7795272B2 (en) | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
WO2005095401A1 (en) * | 2004-03-22 | 2005-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics |
WO2005116037A1 (en) | 2004-05-24 | 2005-12-08 | Glaxo Group Limited | Purine derivative |
EP2436697A1 (en) | 2004-07-01 | 2012-04-04 | Glaxo Group Limited | Chimeric and humanised monoclonal antibodies against interleukin-13 |
US7741361B2 (en) | 2004-12-27 | 2010-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7579335B2 (en) | 2005-01-10 | 2009-08-25 | Glaxo Group Limited | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
WO2006104889A2 (en) | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Novel compounds |
EP2447266A1 (en) | 2005-03-25 | 2012-05-02 | Glaxo Group Limited | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator |
EP2436686A1 (en) | 2005-03-25 | 2012-04-04 | Glaxo Group Limited | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator |
US7622594B2 (en) | 2005-06-10 | 2009-11-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
JP2008543780A (en) * | 2005-06-10 | 2008-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucocorticoid mimetics, methods for their production, pharmaceutical compositions and their use |
WO2006135826A1 (en) * | 2005-06-10 | 2006-12-21 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2007022824A1 (en) * | 2005-06-24 | 2007-03-01 | Bayer Schering Pharma Aktiengesellschaft | Use of non-steroidal progesterone receptor modulators |
DE102005030293A1 (en) * | 2005-06-24 | 2007-01-04 | Schering Ag | Use of nonsteroidal progesterone receptor modulators |
US7408060B2 (en) | 2005-06-24 | 2008-08-05 | Schering Ag | Nonsteroidal progesterone receptor modulators |
DE102005030294A1 (en) * | 2005-06-24 | 2007-01-04 | Schering Ag | Nonsteroidal progesterone receptor modulators |
WO2007009757A1 (en) | 2005-07-19 | 2007-01-25 | Glaxo Group Limited | Purine derivatives as agonists of the adenosine a2a receptor |
EP2157087A1 (en) | 2005-12-20 | 2010-02-24 | Glaxo Group Limited | 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders |
WO2007122165A1 (en) | 2006-04-20 | 2007-11-01 | Glaxo Group Limited | Novel compounds |
WO2007144327A2 (en) | 2006-06-12 | 2007-12-21 | Glaxo Group Limited | Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands |
WO2008027796A2 (en) | 2006-08-31 | 2008-03-06 | Bausch & Lomb Incorporated | Compositions and methods for treating or preventing glaucoma or progression thereof |
EP2397140A1 (en) * | 2006-08-31 | 2011-12-21 | Bausch & Lomb Incorporated | Compositions and methods for treating or preventing glaucoma or progression thereof |
WO2008027796A3 (en) * | 2006-08-31 | 2008-09-12 | Bausch & Lomb | Compositions and methods for treating or preventing glaucoma or progression thereof |
WO2008043789A1 (en) * | 2006-10-13 | 2008-04-17 | Glaxo Group Limited | Novel compounds |
US7947727B2 (en) | 2006-10-13 | 2011-05-24 | GlaxoGroupLimited | Compounds |
US7968577B2 (en) | 2006-11-01 | 2011-06-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
WO2008070507A2 (en) * | 2006-12-06 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
JP2010512331A (en) * | 2006-12-06 | 2010-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucocorticoid mimetics, methods for their production, pharmaceutical compositions, and uses thereof |
US8658637B2 (en) | 2006-12-06 | 2014-02-25 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
WO2008070507A3 (en) * | 2006-12-06 | 2008-09-12 | Boehringer Ingelheim Int | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2008077647A3 (en) * | 2006-12-21 | 2008-10-16 | Bayer Schering Pharma Ag | Alpha- amino alcohols as non-steroidal progesterone receptor modulators |
WO2008077647A2 (en) * | 2006-12-21 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Alpha- amino alcohols as non-steroidal progesterone receptor modulators |
WO2008118724A1 (en) | 2007-03-23 | 2008-10-02 | Smithkline Beecham Corporation | Indole carboxamides as ikk2 inhibitors |
WO2009071252A1 (en) * | 2007-12-05 | 2009-06-11 | Bayer Schering Pharma Aktiengesellschaft | Nonsteroidal progesterone receptor modulators |
DE102007058747A1 (en) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nonsteroidal progesterone receptor modulators |
WO2010068311A1 (en) | 2008-05-23 | 2010-06-17 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein inhibitor |
WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
WO2009147187A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
US8268859B2 (en) | 2008-06-06 | 2012-09-18 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
WO2010102958A1 (en) | 2009-03-09 | 2010-09-16 | Glaxo Group Limited | 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
WO2010106016A1 (en) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107955A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING |
WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010122089A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | N-pyrazolyl carboxamides as crac channel inhibitors |
WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
EP2899191A1 (en) | 2009-04-30 | 2015-07-29 | Glaxo Group Limited | Oxazole substituted indazoles as pi3-kinase inhibitors |
EP3260453A1 (en) | 2009-04-30 | 2017-12-27 | Glaxo Group Limited | Oxazole substituted indazoles as pi3-kinase inhibitors |
WO2011067366A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
WO2011084316A2 (en) | 2009-12-16 | 2011-07-14 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
EP3020393A1 (en) | 2009-12-16 | 2016-05-18 | 3M Innovative Properties Company of 3M Center | Formulations and methods for controlling mdi particle size delivery |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
WO2011134971A1 (en) | 2010-04-29 | 2011-11-03 | Glaxo Group Limited | 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors |
WO2012032067A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide |
WO2012032065A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
WO2012052458A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
EP3447055A1 (en) | 2010-10-27 | 2019-02-27 | Glaxo Group Limited | Combinations of polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders |
WO2012055846A1 (en) | 2010-10-27 | 2012-05-03 | Glaxo Group Limited | Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5- { [4-(1-methylethyl)-1-pi perazinyl] methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders |
WO2012123311A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk) |
WO2012123312A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
EP2937344A1 (en) | 2011-03-11 | 2015-10-28 | Glaxo Group Limited | Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk) |
WO2012170175A1 (en) * | 2011-06-07 | 2012-12-13 | Bausch & Lomb Incorporated | Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain |
WO2015042078A2 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
WO2015042077A1 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
WO2015055690A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
WO2015055691A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
EP3327006A1 (en) | 2014-03-28 | 2018-05-30 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
EP3312164A1 (en) | 2014-03-28 | 2018-04-25 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
WO2017137535A1 (en) | 2016-02-12 | 2017-08-17 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as inhibitors of kinase activity |
WO2018029126A1 (en) | 2016-08-08 | 2018-02-15 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
WO2018192864A1 (en) | 2017-04-18 | 2018-10-25 | Glaxosmithkline Intellectual Property Development Limited | Oxepinopyrazole derivatives as inhibitors of pi3-kinase activity |
WO2019020657A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridine-3-sulfonamide compounds as pi3-kinase inhibitors |
WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
WO2019143874A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
WO2021191875A1 (en) | 2020-03-26 | 2021-09-30 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Also Published As
Publication number | Publication date |
---|---|
US7189758B2 (en) | 2007-03-13 |
ATE346058T1 (en) | 2006-12-15 |
DE60309829T2 (en) | 2007-09-13 |
EP1467982B1 (en) | 2006-11-22 |
EP1467982B8 (en) | 2007-04-11 |
AU2003202216A1 (en) | 2003-07-30 |
EP1467982A1 (en) | 2004-10-20 |
JP2005519897A (en) | 2005-07-07 |
US20030232823A1 (en) | 2003-12-18 |
DE60309829D1 (en) | 2007-01-04 |
US20060030561A1 (en) | 2006-02-09 |
ES2276038T3 (en) | 2007-06-16 |
CA2472746A1 (en) | 2003-07-24 |
US6960581B2 (en) | 2005-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1467982B1 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof | |
US7186864B2 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
US7074806B2 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
US7795272B2 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | |
EP1490062B1 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
US6858627B2 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
US20040224992A1 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
US7741361B2 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
US20050234091A1 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | |
US20040029932A1 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
US20090176807A1 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003701228 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2472746 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003560002 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003701228 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003701228 Country of ref document: EP |